Zacks Investment Research Lowers Pharvaris (NASDAQ:PHVS) to Sell

Zacks Investment Research downgraded shares of Pharvaris (NASDAQ:PHVS) from a hold rating to a sell rating in a research note published on Saturday, Zacks.com reports.

According to Zacks, “Pharvaris N.V. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema and other bradykinin-B2-receptor-mediated indications. Pharvaris N.V. is based in ZUG, Switzerland. “

Shares of Pharvaris stock opened at $19.00 on Friday. The company has a market capitalization of $604.96 million and a P/E ratio of -3.10. The business has a 50-day moving average of $17.21 and a two-hundred day moving average of $21.40. Pharvaris has a 1 year low of $13.14 and a 1 year high of $42.86.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Friday, July 30th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.50). On average, equities research analysts expect that Pharvaris will post -2.59 EPS for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rokos Capital Management LLP acquired a new stake in shares of Pharvaris in the first quarter valued at approximately $68,000. Davidson Kempner Capital Management LP acquired a new stake in Pharvaris in the 1st quarter valued at $98,000. Morgan Stanley bought a new stake in Pharvaris during the 1st quarter worth about $135,000. Ensign Peak Advisors Inc bought a new stake in Pharvaris during the 1st quarter worth about $140,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of Pharvaris by 18.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 16,434 shares of the company’s stock worth $299,000 after buying an additional 2,560 shares during the last quarter. 69.08% of the stock is currently owned by hedge funds and other institutional investors.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).

Read More: What is the quiet period?

Get a free copy of the Zacks research report on Pharvaris (PHVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.